Compare Merck & Co., Inc. (MRK) vs Victoria's Secret & Co (VSXY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs Victoria's Secret & Co — how do they compare? Merck & Co., Inc. trades at $146.05 (market cap $351.28B), while Victoria's Secret & Co trades at $82.86 (market cap $6.91B). The key difference: Merck & Co., Inc. is far larger — about 50.8× Victoria's Secret & Co's market cap, and Merck & Co., Inc. pays a 2.39% dividend while Victoria's Secret & Co pays none. Which is the better fit depends on your goals — on Pluang, investors hold Merck & Co., Inc. for 98 Days and Victoria's Secret & Co for 34 Days on average.
| MRK | VSXY | |
|---|---|---|
Market Cap | $351.28B | $6.91B |
Volume | 7,969,665 | 1,346,928 |
Sector | Health | Consumer Cyclical |
52-Week High | $156.43 | $99.97 |
52-Week Low | $82.49 | $28.25 |
Typical Hold Time | 98 Days | 34 Days |
Enterprise Value | $398.04B | $9.29B |
Dividend Yield | 2.39% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $145.6, up 1.97% today, with a bearish technical signal but strong fundamental performance. Recent earnings have consistently beaten estimates, and the company is expanding its oncology pipeline through the acquisition of Terns Pharmaceuticals. Revenue growth is steady, with 2025 revenue at $65.01B and net income of $18.25B, though 2026 projections show a significant drop in net income to $3.2B. The stock is supported by a high analyst buy consensus of 68.42% and a price target of $158.78.
The outlook for MRK is mixed; strong earnings beats and strategic acquisitions provide upside potential, but high valuation ratios and a projected earnings decline in 2026 pose risks. Investors should weigh the company's robust profitability and analyst support against execution risks and market volatility.
Victoria's Secret (VSXY) trades at $82.87, down 3.4% on the day, but maintains strong analyst support with a 60% buy rating and $86.80 consensus price target. The stock shows bullish technical momentum with recent earnings beats in Q4 2025 and Q1-Q2 2026, while fundamentals reveal improving profitability with 39.57% gross margins and 45.27% ROE. Recent news highlights brand momentum through fashion show expansions and omnichannel retail growth.
The outlook remains positive with projected 2026 revenue growth to $6.9B and net income of $378M, though risks include elevated valuation metrics (P/E 19.33) and competitive pressures. Institutional interest is strengthening with recent investments from Tidal Investments and California State Teachers Retirement System, supporting the bullish case for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About Victoria's Secret & Co
Victoria's Secret & Co is a specialty retailer of lingerie, pajamas, and beauty products with prestige fragrances and body care. It serves customers at its Lingerie and Beauty stores around the globe and online enabling them to shop the brand anywhere and anytime.
Read more on VSXY →
